Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermacyd PH_DETINBACK Sweet Flower · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINBACK (Lactic Acid) Sweet Flower |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower | DRUG | - |
Inclusion criteria: * Integral skin test in the region; * Use of cosmetic product of the same category; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time; Exclusion criteria: * Lactation or gestational risk or gestation; * Use of Anti-i...
Dermacyd PH_DETINBACK Sweet Flower is a small molecule product developed for hygiene purposes. It is intended for use in maintaining hygiene, as indicated in clinical trials. The product is currently in Phase 3 clinical development and is being studied for safety in healthy volunteers.
Dermacyd PH_DETINBACK Sweet Flower is developed by Sanofi, a global biopharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY. The product is being investigated for hygiene applications and is currently in Phase 3 clinical trials.
Dermacyd PH_DETINBACK Sweet Flower is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the product is being studied for safety in healthy volunteers.
Dermacyd PH_DETINBACK Sweet Flower has one completed clinical trial with the identifier NCT00785850. This Phase 3 trial, titled 'Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety,' enrolled 31 female participants aged 10 years and older in Brazil. The trial was uncontrolled and not blinded.
Dermacyd PH_DETINBACK Sweet Flower is not FDA approved. It is an investigational product currently in Phase 3 clinical development. The completed trial focused on safety in healthy volunteers, and the product has not yet received regulatory approval for marketing.